These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 23809696)

  • 1. Peripheral blood derived gene panels predict response to infliximab in rheumatoid arthritis and Crohn's disease.
    Mesko B; Poliska S; Váncsa A; Szekanecz Z; Palatka K; Hollo Z; Horvath A; Steiner L; Zahuczky G; Podani J; Nagy AL
    Genome Med; 2013; 5(6):59. PubMed ID: 23809696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood-based identification of non-responders to anti-TNF therapy in rheumatoid arthritis.
    Thomson TM; Lescarbeau RM; Drubin DA; Laifenfeld D; de Graaf D; Fryburg DA; Littman B; Deehan R; Van Hooser A
    BMC Med Genomics; 2015 Jun; 8():26. PubMed ID: 26036272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of inflammatory mediators in patients with Crohn's disease unresponsive to anti-TNFα therapy.
    Leal RF; Planell N; Kajekar R; Lozano JJ; Ordás I; Dotti I; Esteller M; Masamunt MC; Parmar H; Ricart E; Panés J; Salas A
    Gut; 2015 Feb; 64(2):233-42. PubMed ID: 24700437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
    Sekiguchi N; Kawauchi S; Furuya T; Inaba N; Matsuda K; Ando S; Ogasawara M; Aburatani H; Kameda H; Amano K; Abe T; Ito S; Takeuchi T
    Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease.
    Arijs I; Quintens R; Van Lommel L; Van Steen K; De Hertogh G; Lemaire K; Schraenen A; Perrier C; Van Assche G; Vermeire S; Geboes K; Schuit F; Rutgeerts P
    Inflamm Bowel Dis; 2010 Dec; 16(12):2090-8. PubMed ID: 20848504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis.
    Lequerré T; Gauthier-Jauneau AC; Bansard C; Derambure C; Hiron M; Vittecoq O; Daveau M; Mejjad O; Daragon A; Tron F; Le Loët X; Salier JP
    Arthritis Res Ther; 2006; 8(4):R105. PubMed ID: 16817978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of candidate genes for rituximab response in rheumatoid arthritis patients by microarray expression profiling in blood cells.
    Julià A; Barceló M; Erra A; Palacio C; Marsal S
    Pharmacogenomics; 2009 Oct; 10(10):1697-708. PubMed ID: 19842941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
    Keating GM; Perry CM
    BioDrugs; 2002; 16(2):111-48. PubMed ID: 11985485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis.
    Choi IY; Gerlag DM; Herenius MJ; Thurlings RM; Wijbrandts CA; Foell D; Vogl T; Roth J; Tak PP; Holzinger D
    Ann Rheum Dis; 2015 Mar; 74(3):499-505. PubMed ID: 24297376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-treatment whole blood gene expression is associated with 14-week response assessed by dynamic contrast enhanced magnetic resonance imaging in infliximab-treated rheumatoid arthritis patients.
    MacIsaac KD; Baumgartner R; Kang J; Loboda A; Peterfy C; DiCarlo J; Riek J; Beals C
    PLoS One; 2014; 9(12):e113937. PubMed ID: 25504080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn's disease and rheumatoid arthritis: results of a systematic review.
    Fidder HH; Singendonk MM; van der Have M; Oldenburg B; van Oijen MG
    World J Gastroenterol; 2013 Jul; 19(27):4344-50. PubMed ID: 23885145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral blood gene expression and IgG glycosylation profiles as markers of tocilizumab treatment in rheumatoid arthritis.
    Mesko B; Poliska S; Szamosi S; Szekanecz Z; Podani J; Varadi C; Guttman A; Nagy L
    J Rheumatol; 2012 May; 39(5):916-28. PubMed ID: 22467923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis.
    Liu Y; Wu EQ; Bensimon AG; Fan CP; Bao Y; Ganguli A; Yang M; Cifaldi M; Mulani P
    Adv Ther; 2012 Jul; 29(7):620-34. PubMed ID: 22843208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromosome conformation signatures define predictive markers of inadequate response to methotrexate in early rheumatoid arthritis.
    Carini C; Hunter E; ; Ramadass AS; Green J; Akoulitchev A; McInnes IB; Goodyear CS
    J Transl Med; 2018 Jan; 16(1):18. PubMed ID: 29378619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential gene expression profiles may differentiate responder and nonresponder patients with rheumatoid arthritis for methotrexate (MTX) monotherapy and MTX plus tumor necrosis factor inhibitor combined therapy.
    Oliveira RD; Fontana V; Junta CM; Marques MM; Macedo C; Rassi DM; Passos GA; Donadi EA; Louzada-Junior P
    J Rheumatol; 2012 Aug; 39(8):1524-32. PubMed ID: 22753658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients.
    Raterman HG; Vosslamber S; de Ridder S; Nurmohamed MT; Lems WF; Boers M; van de Wiel M; Dijkmans BA; Verweij CL; Voskuyl AE
    Arthritis Res Ther; 2012 Apr; 14(2):R95. PubMed ID: 22540992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An eight-gene blood expression profile predicts the response to infliximab in rheumatoid arthritis.
    Julià A; Erra A; Palacio C; Tomas C; Sans X; Barceló P; Marsal S
    PLoS One; 2009 Oct; 4(10):e7556. PubMed ID: 19847310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating Biomarkers for Predicting Infliximab Response in Rheumatoid Arthritis: A Systematic Bioinformatics Analysis.
    Huang QL; Zhou FJ; Wu CB; Xu C; Qian WY; Fan DP; Cai XS
    Med Sci Monit; 2017 Apr; 23():1849-1855. PubMed ID: 28413214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene profiling predicts rheumatoid arthritis responsiveness to IL-1Ra (anakinra).
    Bansard C; Lequerré T; Derambure C; Vittecoq O; Hiron M; Daragon A; Pouplin S; Daveau M; Boyer O; Tron F; Le Loët X; Salier JP
    Rheumatology (Oxford); 2011 Feb; 50(2):283-92. PubMed ID: 21059672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of serum anti-centromere protein F antibodies with clinical response to infliximab in patients with rheumatoid arthritis: A prospective study.
    Lourido L; Ruiz-Romero C; Picchi F; Diz-Rosales N; Vilaboa-Galán S; Fernández-López C; Tasende JAP; Pérez-Pampín E; Regueiro C; Mera-Varela A; Gonzalez A; Hambardzumyan K; Saevarsdottir S; Nilsson P; Blanco FJ
    Semin Arthritis Rheum; 2020 Oct; 50(5):1101-1108. PubMed ID: 32920323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.